Research map: Concurrent mGlu2-mGlu4 receptor positive allosteric modulation for L-DOPA-induced treatment-induced complications in the parkinsonian marmoset

Back to the article

Papers in this map

  1. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years · Mariese A. Hely · 2008 · 2276 citations · Cited by this paper
  2. Congenital Kir6.2 deficiency, but not acute KATP channel blockade, attenuates apomorphine-induced locomotor activity in mice · 2026 · Related
  3. Challenges in the diagnosis of Parkinson's disease · EDUARDO S. TOLOSA · 2021 · 1886 citations · Cited by this paper
  4. Simultaneous modulation of 5-HT6 and SERT by MM394: a dual-target ligand providing neuroprotection against amyloid-β toxicity, memory preservation, and alleviation of BPSD symptoms · 2025 · Related
  5. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders · P. Jeffrey Conn · 2008 · 1063 citations · Cited by this paper
  6. Acute elevation of anandamide and 2-AG levels modulates defensive behavior in a sex- and strain-dependent manner in an animal model of attention-deficit/hyperactivity disorder · 2026 · Related
  7. Sydney multicenter study of Parkinson's disease: Non‐ L ‐dopa–responsive problems dominate at 15 years · Mariese A. Hely · 2004 · 1055 citations · Cited by this paper
  8. Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol · 2026 · Related
  9. International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease · Susan Helen Fox · 2018 · 1011 citations · Cited by this paper
  10. Antiseizure properties of new selenobenzimidazole derivatives: A pre-clinical study in a neonatal model of epilepsy · 2026 · Related
  11. Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States · Jose Ma. J. Alvir · 1993 · 977 citations · Cited by this paper
  12. The silent weight of stress: A biopsycholinguistic loop of cortisol, control, and the language of the self · 2026 · Related
  13. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial · Jeffrey L. Cummings · 2013 · 958 citations · Cited by this paper
  14. Post-conditioning catecholaminergic antagonism fails to alter methamphetamine sensitization in mice · 2025 · Related
  15. Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease · The Parkinson Study Group · 1999 · 615 citations · Cited by this paper
  16. Adolescent stress differentially modulates the affective, psychomotor, and neural responses to a first amphetamine exposure in male Wistar rats · 2025 · Related
  17. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria · Günter U. Höglinger · 2024 · 549 citations · Cited by this paper
  18. Inhibition of compulsive behavior by dextromethorphan on schedule-induced polydipsia in rats: Role of NMDA, sigma-1, and 5-HT receptors · 2026 · Related
  19. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients With Parkinson Disease and Motor Fluctuations · Parkinson Study Group · 2005 · 418 citations · Cited by this paper
  20. Sex differences among adult and adolescent rats in METH-induced CTA with extended CS-US trace intervals · 2026 · Related
  21. The temporal lobe is a target of output from the basal ganglia. · Frank A. Middleton · 1996 · 303 citations · Cited by this paper
  22. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment · Michael J. Marino · 2003 · 241 citations · Cited by this paper
  23. Clozapine in drug-induced psychosis in Parkinson's disease · 1999 · 229 citations · Cited by this paper
  24. Chronic L ‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) · R. K. B. Pearce · 1995 · 220 citations · Cited by this paper
  25. Amantadine in the treatment of Parkinson's disease and other movement disorders · Olivier Rascol · 2021 · 210 citations · Cited by this paper
  26. Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2− trifluoroethylsulfonyl)pyrid-3-ylmethylamine · Michael P. Johnson · 2003 · 183 citations · Cited by this paper
  27. Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse · Ornella Valenti · 2003 · 166 citations · Cited by this paper
  28. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) · Michael P. Johnson · 2005 · 156 citations · Cited by this paper
  29. Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS · Yin Shen · 2013 · 136 citations · Cited by this paper
  30. The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson’s Disease · Carrie K. Jones · 2011 · 104 citations · Cited by this paper
  31. Double-blind, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Stable Parkinson Disease · C. Warren Olanow · 2004 · 104 citations · Cited by this paper
  32. A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's Disease · Emmanuel Le Poul · 2012 · 102 citations · Cited by this paper
  33. Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells · David Moreno‐Delgado · 2017 · 99 citations · Cited by this paper
  34. Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia · Khaled-Ezaheir Bennouar · 2012 · 98 citations · Cited by this paper
  35. Striatal glutamatergic hyperactivity in Parkinson's disease · Federica Campanelli · 2022 · 88 citations · Cited by this paper
  36. Safety of Selegiline (Deprenyl) in the Treatment of Parkinson??s Disease · Esa H. Heinonen · 1998 · 87 citations · Cited by this paper
  37. AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study · Robert E. Litman · 2016 · 87 citations · Cited by this paper
  38. Functional and Pharmacological Characteristics of Metabotropic Glutamate Receptors 2/4 Heterodimers · Paul J. Kammermeier · 2012 · 77 citations · Cited by this paper
  39. Allosteric control of an asymmetric transduction in a G protein-coupled receptor heterodimer · Junke Liu · 2017 · 76 citations · Cited by this paper

Source: OpenAlex (CC0)